GT Biopharma (NASDAQ: GTBP) wins approval for reverse split and share plan changes
Rhea-AI Filing Summary
GT Biopharma, Inc. held its Annual Meeting of Stockholders on August 14, 2026. Holders of 44,338,573 common shares were eligible, and 23,357,724 shares (about 52.68%) were represented, constituting a quorum. Stockholders elected four directors and ratified Weinberg & Company, P.A. as independent accountants for the year ending December 31, 2026. They approved, on a non-binding advisory basis, the Company’s executive compensation. Stockholders also approved an amendment authorizing a reverse stock split in a 1-for-10 to 1-for-30 range plus a reduction of authorized stock to 25,000,000 common and 1,500,000 preferred shares, to be implemented at the Board’s discretion within one year. In addition, they approved a 3,500,000-share increase to the 2022 Omnibus Incentive Plan and an evergreen provision for automatic annual increases.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.07, 9.01
2 items
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares outstanding: 44,338,573 shares
Shares represented at meeting: 23,357,724 shares
Reverse split range: 1-for-10 to 1-for-30
+5 more
8 metrics
Shares outstanding
44,338,573 shares
Common stock outstanding and entitled to vote as of June 30, 2026
Shares represented at meeting
23,357,724 shares
Common shares present or represented by proxy (about 52.68% of eligible)
Reverse split range
1-for-10 to 1-for-30
Approved range for reverse stock split of issued and outstanding common stock
Authorized common stock
25,000,000 shares
New authorized common shares approved in charter amendment
Authorized preferred stock
1,500,000 shares
New authorized preferred shares approved in charter amendment
Incentive plan share increase
3,500,000 shares
Additional common shares available for future awards under the 2022 Omnibus Incentive Plan
Auditor ratification votes for
22,687,907 votes
Votes in favor of ratifying Weinberg & Company, P.A. for 2026
Reverse split proposal votes for
18,077,466 votes
Votes in favor of the charter amendment authorizing reverse split and share reduction
Key Terms
reverse stock split, broker non-votes, evergreen provision, non-binding advisory basis, +1 more
5 terms
reverse stock split financial
"to effect (i) a reverse stock split with respect to the Company’s issued"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
broker non-votes financial
"as well as the number of abstentions and broker non-votes with respect"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
evergreen provision financial
"a second and separate amendment to the 2022 Plan to adopt an evergreen provision"
An evergreen provision is a clause in a financing or contract that automatically renews or replenishes the arrangement unless one party actively cancels it, like a subscription that keeps renewing each term. For investors it matters because it creates predictable, ongoing access to funding or ongoing contractual obligations — helping liquidity and planning — but can also hide long-term commitments or dilution risks if not reviewed.
non-binding advisory basis financial
"approve, on a non-binding advisory basis, the Company’s executive compensation"
A non-binding advisory basis is guidance or a recommendation offered for informational purposes that does not create legal obligations or guarantees; recipients can accept, modify, or ignore it without contractual consequences. Investors should treat it like a weather forecast for planning—useful for forming expectations and assessing risk, but not a firm promise—so they should verify assumptions, seek confirming information, and avoid relying on it as the sole basis for investment decisions.
quorum financial
"23,357,724 shares of Common Stock, or approximately 52.68% of the eligible shares, were present ... constituting a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
FAQ
What was the quorum at GTBP's August 14, 2026 Annual Meeting?
The quorum consisted of 23,357,724 shares of common stock, representing about 52.68% of the 44,338,573 shares eligible to vote as of June 30, 2026. This satisfied quorum requirements.
What did GTBP approve regarding its 2022 Omnibus Incentive Plan?
Shareholders approved increasing shares available under the 2022 Plan by 3,500,000 common shares and adopting an evergreen provision that provides for automatic annual increases in available shares for future awards.
Was GTBP’s executive compensation approved on a say-on-pay basis?
Yes. The non-binding advisory proposal on executive compensation received 6,057,507 votes for, 2,162,518 against, and 310,220 abstentions, with 14,827,479 broker non-votes.
Where can GTBP stockholder communications be sent now that the company is fully remote?
Effective July 1, 2024, GT Biopharma became fully remote. Stockholder communications may be directed to 505 Montgomery Street, 10th Floor, San Francisco, CA 94111, or by email to auditcommittee@gtbiopharma.com.
AI-generated analysis. How Rhea-AI works. Not financial advice.
